Myo-Inositol

What Myo-Inositol Actually Is

Inositol is a six-carbon sugar alcohol with nine possible arrangements of its hydroxyl groups. Two matter here. Myo-inositol is the abundant one — made in the kidney, present in cereals, legumes and fruit, and the backbone of the phosphatidylinositol lipids in every cell membrane. D-chiro-inositol is made from it by an insulin-dependent epimerase, at rates that vary from tissue to tissue.

Both are precursors of the inositol phosphoglycan mediators that carry insulin's message from the receptor into the cell. That is the whole rationale for supplementation: if a tissue is short of the building block for the second messenger, insulin binds its receptor and the signal goes nowhere. Myo-inositol is sold to relieve that bottleneck.

It is a nutrient, not a drug. The doses used in trials — 4 g/day — are above what diet provides but well inside the range the body handles without difficulty.

The PCOS Evidence

This is where the profile earns its grade, and it is worth being specific about what the meta-analyses actually found.

The 2017 meta-analysis pooled nine randomised trials, 247 treated and 249 controls. Myo-inositol lowered fasting insulin (SMD −1.02, 95% CI −1.79 to −0.25, P = 0.009) and the HOMA index (SMD −0.59, 95% CI −1.15 to −0.03, P = 0.041). Trial sequential analysis confirmed the insulin result was not a small-sample artefact. Testosterone trended down without reaching significance (P = 0.099), and SHBG rose significantly only in trials of at least 24 weeks.

The 2023 meta-analysis was larger — 26 randomised trials, 1,691 women, with placebo and metformin comparators. Women on inositol were 1.79 times more likely to have a regular menstrual cycle than on placebo (95% CI 1.13–2.85). Free testosterone, total testosterone, androstenedione, glucose and the insulin area under the curve all fell against placebo, and SHBG rose (MD 32.1, 95% CI 1.3–62.9). Against metformin, inositol was non-inferior for cycle regularity and most secondary outcomes.

A meta-analysis limited to head-to-head comparisons — eight trials, 1,088 women — found no significant difference between myo-inositol and metformin on BMI, fasting insulin, fasting glucose, HOMA index or the LH/FSH ratio. For a woman with PCOS who cannot tolerate metformin's gastrointestinal effects, that is a meaningful result.

The formulation matters. A seven-arm trial gave 56 women 2 g of inositols twice daily for three months across ratios from D-chiro-inositol alone to 80:1. The 40:1 myo:D-chiro ratio — which matches plasma — was best at restoring ovulation, and shifting the ratio toward D-chiro-inositol lost the reproductive benefit. The mechanism behind that is the ovarian paradox: the ovary of an insulin-resistant woman is hypothesised to over-convert myo-inositol into D-chiro-inositol, so flooding it with more D-chiro-inositol makes the local deficit worse.

One honest caveat on the trial base. The earliest placebo-controlled myo-inositol trials in PCOS came from a single Italian group, and the 2007 paper was retracted in 2023 as a duplicate of the 2003 paper, which itself carries an expression of concern. The meta-analyses above still hold on the remaining trials, but the field's foundations are less solid than its citation counts suggest.

Gestational Diabetes: Two Answers

The 2023 Cochrane review pooled seven trials and 1,319 pregnant women and found myo-inositol may reduce gestational diabetes (RR 0.53, 95% CI 0.31–0.90), hypertensive disorders of pregnancy (RR 0.34) and preterm birth (RR 0.35). The certainty was rated low to very low: the trials were small, six of the seven were Italian, and doses and timing were inconsistent.

Then the trial that should have confirmed it did not. A Dutch randomised, double-blind, placebo-controlled trial across 13 hospitals gave 464 pregnant women with PCOS myo-inositol 2 g twice daily from 8–16 weeks' gestation to delivery. The composite of gestational diabetes, pre-eclampsia or preterm birth occurred in 25.0% on myo-inositol versus 26.8% on placebo (RR 0.93, 95% CI 0.68–1.28, P = 0.67). No effect.

That trial is larger and better controlled than any in the Cochrane pool. It does not erase the earlier signal in general obstetric populations, but it removes the claim that myo-inositol reliably prevents pregnancy complications in women with PCOS — the group most often told to take it for that reason.

What Myo-Inositol Has Never Shown

• Live birth. The 2018 Cochrane review of 13 trials in 1,472 subfertile women with PCOS was uncertain whether myo-inositol improves live birth (OR 2.42, 95% CI 0.75–7.83, two trials, 84 women) or clinical pregnancy. The apparent reduction in miscarriage disappeared when a single trial with an unusually high control-group rate was removed.
• Hard metabolic outcomes outside PCOS. There is no trial showing that myo-inositol reduces progression to type 2 diabetes, cardiovascular events, or anything beyond fasting insulin and HOMA-IR in people with metabolic syndrome who do not have PCOS. Its general glycaemic grade on this site is C for that reason.
• Weight loss. The BMI effect in the 2023 meta-analysis was a mean difference of −0.45 kg/m² — statistically significant, clinically marginal.
• Pregnancy complications in PCOS. Tested properly in 2025 and negative.

Dosing

Powder dissolved in water is the practical form; 4 g in capsules is eight to ten pills. Take it with or without food. There is no evidence that exceeding 4 g/day adds anything for metabolic endpoints.

Who This Is Reasonable For

Myo-inositol is defensible for a woman with PCOS who wants an insulin sensitiser and either cannot tolerate metformin or prefers to try a non-pharmaceutical route first, with the understanding that cycle regularity and fasting insulin are the endpoints it moves and live birth is not one it has demonstrated. It is a reasonable fork in The Insulin Sensitivity Protocol for exactly that population.

For a man with metabolic syndrome, or a woman without PCOS, the case is weaker: the mechanism is intact but the outcome trials do not exist. Cheap and safe enough to try; not something to build a plan around.

Related Research

• Myo-Inositol: The Insulin Sensitiser for PCOS and Beyond
• The Insulin Sensitivity Stack: Berberine + Inositol + ALA + Chromium
• The Insulin Sensitivity Protocol
• Berberine vs. Metformin